Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PDLI PDL BioPharma (PDLI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About PDL BioPharma Stock (NASDAQ:PDLI) 30 days 90 days 365 days Advanced Chart Ad The Oxford ClubOil Prices Surge Due to Israel-Iran ConflictHeightened tension in the Middle East has created a huge supply shock to the global oil industry. But… I’ve found a new way to invest in oil right here in the US.All the details are right here. Get PDL BioPharma alerts:Sign Up Key Stats Today's Range$2.47▼$2.4750-Day Range$2.47▼$2.4752-Week Range$2.09▼$3.86VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.Read More… Oil Prices Surge Due to Israel-Iran Conflict (Ad)Heightened tension in the Middle East has created a huge supply shock to the global oil industry. But… I’ve found a new way to invest in oil right here in the US.All the details are right here. Receive PDLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PDL BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address PDLI Stock News HeadlinesGT Biopharma Inc GTBPFebruary 23, 2024 | morningstar.comHealth Winners & Losers: MaxygenOctober 24, 2023 | thestreet.comWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.October 10, 2024 | Angel Publishing (Ad)PDLI Historical DataOctober 18, 2023 | investing.comABVC - ABVC BioPharma, Inc.June 28, 2023 | finance.yahoo.comRDHL - RedHill Biopharma Ltd.June 23, 2023 | finance.yahoo.comLABPMarch 12, 2023 | seekingalpha.comA Persons Deprived of Liberty (PDL) interacts with his pet mouse inside the jailJanuary 15, 2023 | msn.comSee More Headlines PDLI Stock Analysis - Frequently Asked Questions How were PDL BioPharma's earnings last quarter? PDL BioPharma, Inc. (NASDAQ:PDLI) posted its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.10 by $0.53. The biotechnology company had revenue of $5.21 million for the quarter. What other stocks do shareholders of PDL BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that PDL BioPharma investors own include AT&T (T), OPKO Health (OPK), Advanced Micro Devices (AMD), Novavax (NVAX), General Electric (GE) and Teva Pharmaceutical Industries (TEVA). Company Calendar Last Earnings8/06/2020Today10/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:PDLI CUSIP69329Y10 CIK882104 Webwww.pdl.com Phone775-832-8500Fax775-832-8501Employees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:PDLI) was last updated on 10/10/2024 by MarketBeat.com Staff From Our PartnersBigger Than Nvidia?Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the n...InvestorPlace | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | SponsoredAI Expert Reveals New PickWhy You Shouldn't Pour All Your Money Into Nvidia Jeff Brown, who predicted Nvidia's rise, warns against pu...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDL BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDL BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.